Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

 Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

Shots:

  • Ipsen to receive 400,000 shares at closing and an additional 200,000 shares as milestones, $81.63M as development and regulatory milestones & $423.24M as commercial milestones along with royalties on net sales
  • Fusion will be responsible for paying to a third-party licensor up to $84.7M in development milestones and royalties on net sales of products
  • IPN-1087 is a small molecule targeting NTSR1. Fusion plans to use IPN-1087 to create an alpha-emitting radiopharmaceutical, FPI-2059, targeting solid tumors expressing NTSR1

Click here ­to­ read full press release/ article | Ref: PRNewswire  | Image: Fusion Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post